Reblozyl Drives $2.3 Billion Sales and Delivers Positive Alpha-Thalassemia Data
Bristol Myers’ Reblozyl annualized sales have surpassed $2.3 billion, offsetting significant declines in legacy drug revenues with strong US first-line RS-positive and RS-negative MDS demand and robust international launches. Positive ex-US Phase 2 alpha-thalassemia data met primary endpoints in both patient cohorts and support expanded indications.
1. Reblozyl Sales Performance
Reblozyl annualized sales exceed $2.3 billion, driven by strong US uptake in first-line RS-positive and RS-negative MDS and successful international launches in new markets. Bristol Myers expects continued growth from the RS-negative MDS indication and other thalassemia segments to mitigate declines in legacy drug revenues.
2. Phase 2 Alpha-Thalassemia Results
An ex-US Phase 2 registrational study evaluating Reblozyl in alpha-thalassemia met all primary and key secondary endpoints in both non-transfusion-dependent and transfusion-dependent cohorts, showing significant hemoglobin increases and reduced red blood cell transfusion burden with a consistent safety profile. These data will be presented at an upcoming medical meeting and used in regulatory discussions, including with China’s regulator.
3. Competitive Landscape and Outlook
Reblozyl faces competition from Keros Therapeutics’ elritercept in Phase III and Geron’s Rytelo, which generated $183.6 million in 2025 and is expected to reach $220–$240 million in 2026. Approval in additional geographies and expanded indications should further boost Bristol Myers’ top-line growth and strengthen its market position in MDS-related anemia.